Clinical Trials
14 trialsNCT04483778 2026-04-28
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
Phase 1 Active not recruiting
NCT03618381 2025-11-20
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
Phase 1 Active not recruiting
NCT01661400 2024-01-31
ASCR
Washington University School of Medicine
Phase 1 Completed
NCT01331135 2020-05-29
Aflac ST0901
Emory University
Phase 1 Completed
NCT02390843 2020-04-03
AflacST1402
Emory University
Phase 1 Completed
NCT00623077 2017-12-05
MT2004-30: Tomotherapy for Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT00003926 2017-11-29
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT01598454 2015-07-29
Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides
Laboratorio Elea Phoenix S.A.
Phase 1 Completed
NCT00003597 2014-07-24
Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors
Children's Oncology Group
Phase 1 Completed
NCT01048892 2014-01-30
Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features
Children's Oncology Group
Phase 1 Completed
NCT00003022 2013-07-03
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00012181 2013-07-02
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Phase 1 Completed
NCT00314925 2010-02-25
Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features
Neotropix
Phase 1 Unknown
NCT00006246 2009-10-07
Busulfan in Treating Children and Adolescents With Refractory CNS Cancer
Pediatric Brain Tumor Consortium
Phase 1 Completed